“…(2016) Day 5 | 100 nM LDN-193189, 3 μM CHIR99021, 100 ng/mL SHH, 2 μM purmorphamine, 100 ng/mL FGF-8 |
Day 7 | 100 nM LDN-193189, 3 μM CHIR99021 |
Day 14 | 20 ng/mL BNDF, 20 ng/mL human recombinant glial-derived neurotrophic factor (GDNF), 0.2 mM ascorbic acid, 1 ng/mL human recombinant transforming growth factor beta (TGFβ), 0.5 mM cyclic AMP (cAMP) | Low cell attachment plates – orbital shaker |
Hindbrain (Brainstem) | Day 1 | 1 mM dorsomorphin, 10 μM SB431542, 10 μM transferrin, 5 mg/L insulin, 0.063 mg/L progesterone | Low attachment multiwell plates; static | Eura et al. (2020) |
Day 9–12 | 20 ng/mL FGF2, 10 μM transferrin, 5 mg/L insulin, 0.063 mg/L progesterone |
Day 13–18 | 20 ng/mL FGF2, 20 ng/mL EGF |
Day 19–25 | ascorbic acid, cAMP, 20 ng/mL BDNF, 20 ng/mL GDNF, 20 ng/mL NT3 |
Hindbrain (Cerebellum) | Day 1 | iPSCs passaged to containers pre-coated with matrigel supplemented with 1% bovine serum albumin | Matrigel plates - static | Valiulahi et al. (2021) |
Day 1 | Knockout serum replacement medium | Low attachment multiwell plates; static |
Day 5 | 25% N2 medium, 2 μM purmorphamine, 2 μM RA |
Day 7 | 50% N2, 2 μM purmorphamine, 2 μM RA |
Day 9 | 75% N2, 2 μM purmorphamine, 2 μM RA |
Day 10–13 | 20 ng/mL BDNF, 2 μM purmorphamine, 2 μM RA | Low cell attachment plates – orbital shaker |
Day 14+ | 20 ng/mL BDNF |
…”